As of Nov 19, 2026, 1 of 2 active firms rate PRTA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PRTA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.36
Range $-0.36 – $-0.36 · 1 analysts · -153% YoY
Next period, 1 analysts expect Prothena Corporation plc to earn $-0.36 a share (range $-0.36 – $-0.36), versus $0.68 a year earlier. Full-year consensus is $0.66, growing to $-1.24 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts · -100% YoY
Revenue is expected to reach $0 (range $0 – $0), -100.0% year-over-year. Full-year consensus is $72.4M, rising to $21.0M next year.
Top analysts covering Prothena Corporation plc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PRTA.
#1
Jason Butler
JMP Securities · Rank #62
Buy
$20.00+139.2% to target
Overall win rate
49%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$30.00+258.9% to target
Overall win rate
45%
+ Follow
#3
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$36.00+330.6% to target
Overall win rate
30%
+ Follow
#4
TA
Tazeen Ahmad
B of A Securities · Rank #411
Sell
$8.00-4.3% to target
Overall win rate
46%
+ Follow
#5
Jay Olson
Oppenheimer · Rank #484
Neutral
No targeton PRTA
Overall win rate
31%
+ Follow
PRTA stock forecast FAQ
What is PRTA's average 12-month price target?+
The 2 active firms with a live target average $16.00 for Prothena Corporation plc over the next 12 months, ranging from a $20.00 high to a $12.00 low, as of Nov 19, 2026.
Is PRTA stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PRTA?+
The Street-high target is $20.00 (Citizens), and the Street-low is $12.00 (RBC Capital). The average of all 2 active-firm targets is $16.00.
How many active Wall Street firms cover PRTA?+
2 active firms have a recognized rating on Prothena Corporation plc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PRTA?+
Among analysts who currently cover PRTA, Jason Butler of JMP Securities has the strongest overall Quantellect track record (Rank #62). Their current call is Buy with a $20.00 target.
What is Prothena Corporation plc's projected EPS for next quarter?+
The consensus estimate is $-0.36 per share (range $-0.36 – $-0.36) across 1 analysts. Full-year EPS is projected at $0.66, rising to $-1.24 the following year.
How much revenue is Prothena Corporation plc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $72.4M, growing to $21.0M next year.
Have analysts been upgrading or downgrading PRTA lately?+
As of Nov 19, 2026, 1 of 2 active firms rate PRTA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PRTA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.